Kurs
+2,56%
Kurs
+2,56%
Open
85,90
High
88,40
Low
85,20
Close
88,00
Kursutveckling under dagen för detta pressmeddelande
(NOK).
Likviditet
32,8 MNOK
Likviditet
32,8 MNOK
Rel. mcap
3,33%
Antal aktier
374 822
Likviditet under dagen för detta pressmeddelande
Kalender
| Tid* | ||
| 2025-02-26 | N/A | Bokslutskommuniké 2024 |
| 2024-11-27 | - | Kvartalsrapport 2024-Q3 |
| 2024-08-21 | - | Kvartalsrapport 2024-Q2 |
| 2024-05-21 | - | X-dag ordinarie utdelning NYKD 0.00 NOK |
| 2024-05-16 | - | Årsstämma |
| 2024-05-14 | - | Kvartalsrapport 2024-Q1 |
| 2024-02-28 | - | Bokslutskommuniké 2023 |
| 2023-11-15 | - | Kvartalsrapport 2023-Q3 |
| 2023-08-23 | - | Kvartalsrapport 2023-Q2 |
| 2023-05-16 | - | Kvartalsrapport 2023-Q1 |
| 2023-05-12 | - | X-dag ordinarie utdelning NYKD 0.00 NOK |
| 2023-05-11 | - | Årsstämma |
| 2023-02-28 | - | Bokslutskommuniké 2022 |
| 2022-11-23 | - | Kvartalsrapport 2022-Q3 |
| 2022-08-24 | - | Kvartalsrapport 2022-Q2 |
| 2022-05-16 | - | Kvartalsrapport 2022-Q1 |
| 2022-05-13 | - | X-dag ordinarie utdelning NYKD 0.00 NOK |
| 2022-05-12 | - | Årsstämma |
| 2022-03-31 | - | Bokslutskommuniké 2021 |
| 2021-12-22 | - | Extra Bolagsstämma 2021 |
| 2021-11-17 | - | Kvartalsrapport 2021-Q3 |
| 2021-08-26 | - | Kvartalsrapport 2021-Q2 |
| 2021-05-12 | - | Kvartalsrapport 2021-Q1 |
| 2021-05-06 | - | X-dag ordinarie utdelning NYKD 0.00 NOK |
| 2021-05-05 | - | Årsstämma |
| 2021-04-21 | - | Bokslutskommuniké 2020 |
| 2020-11-17 | - | Kvartalsrapport 2020-Q3 |
| 2020-08-27 | - | Kvartalsrapport 2020-Q2 |
| 2020-07-07 | - | Split NYKD 1:5 |
| 2020-07-06 | - | Extra Bolagsstämma |
| 2020-05-12 | - | Kvartalsrapport 2020-Q1 |
| 2020-04-22 | - | Extra Bolagsstämma |
Beskrivning
| Land | Norge |
|---|---|
| Lista | OB Match |
| Sektor | Hälsovård |
| Industri | Bioteknik |
2021-06-03 22:50:00
Oslo, Norway, June 3, 2021 - Reference is made to the Annual General Meeting of
Vaccibody AS on May 5, 2021, where the issuance of Restricted Share Units (RSUs)
to the new board member Birgitte Volck was approved. Birgitte Volck has been
granted 4,674 RSUs in line with the terms set out in the minutes from the Annual
General Meeting.
Further, 200,000 share options have been granted to Mikkel Wandahl Pedersen in
connection with his appointment as Chief Scientific Officer. The share options
will have a strike price of NOK 81.14 per share, have a five-year term and will
vest equally over a four-year vesting period. After the award of the share
options, Mikkel Wandahl Pedersen holds a total of 200,000 share options and 0
shares.
Please see further details in attached document.